Clinical trial
Observational Study of Osteoblast Activity in Velcade�(Bortezomib) IV Treated Multiple Myeloma Patients.
NCT01026701 is registered in ClinicalTrials.gov with Janssen Korea, Ltd., Korea as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Observational Study of Osteoblast Activity in Velcade�(Bortezomib) IV Treated Multiple Myeloma Patients.
- Lead sponsor
- Janssen Korea, Ltd., Korea
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2008
- Completion date
- November 30, 2009
- Enrollment
- 104 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.